SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears
Scholar Rock Holding Corp slid 3.2% to $43.76 in afternoon trading on Tuesday after opening at $45.18. The stock traded between $45.95 and $43.74.
Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update
Scholar Rock Holding Corporation is back in the spotlight as its stock jumps more than 25% on the day after a pivotal FDA meeting, fresh Q3 2025 financial results, and the launch of a new $200 million at-the-market stock offering.
Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)
Even as a possible U.S. government shutdown loomed on Capitol Hill, Wall Street managed a modest rise on September 29, 2025. The tech-heavy Nasdaq Composite climbed about 0.5% on the day reuters.com, with investors largely shrugging off fiscal uncertainty. “Investors are clinging to the positives,” noted one strategist, citing hopes of future interest rate cuts and solid economic data reuters.com. Against this cautiously optimistic backdrop, a handful of individual stocks delivered outsized gains thanks to company-specific catalysts – from blockbuster M&A deals to drug approvals and speculative frenzies. Below, we break down the day’s top gainers on U.S. markets and what drove their explosive moves.
Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs
Scholar Rock is a late‑stage biotech developing apitegromab, a selective antibody that blocks latent myostatin activation to build/maintain skeletal muscle. Pipeline also includes SRK‑181 and SRK‑439. Scholar Rock+1
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)
Sources: Ionis HAE drug approval pharmexec.com biopharmadive.com; BioPharmaDive on Dawnzera pricing and positioning biopharmadive.com biopharmadive.com; AbbVie Rinvoq AA trial via FiercePharma fiercepharma.com; Lancet Neurology SAPPHIRE trial results neurologylive.com neurologylive.com; Reuters – Kite/Gilead’s Interius acquisition reuters.com and Interius press release interiusbio.com; PharmExec on XOMA-Mural deal ts2.tech; Reuters – J&J $2B NC facility and quote ts2.tech ts2.tech; Reuters – Apollo Hospitals stake sale ts2.tech; BiopharmaTrend on Kyorin adopting Elix AI platform biopharmatrend.com biopharmatrend.com; Laotian Times – Amgen Golden Ticket and quote ts2.tech ts2.tech; Allos Pharma press release on arbaclofen rights & Dr. Carpenter quote allospharma.com allospharma.com; Allos press – ASD trial results allospharma.com; BiopharmaDive on VC funding and Kriya Therapeutics raise ts2.tech; Neurology Live – Hearing aids & dementia study ts2.tech ts2.tech; NIH news – Phantom limb cortical maps ts2.tech ts2.tech; WHO/UN joint release – Gaza famine declaration who.int; WHO/WMO report on heat stress who.int; Drug Target Review – Chikungunya outbreak global spread drugtargetreview.com drugtargetreview.com; KFF Health News/Washington Post – CDC layoffs & HHS staff letter kffhealthnews.org kffhealthnews.org.